PYRUKYND is also approved for adults with PK deficiency in the U.S. and Europe, and a marketing application for PYRUKYND in thalassemia is currently under review by the European Commission. In the U.S ...

Agios Pharmaceuticals is set to report fourth-quarter and full-year 2025 results Thursday morning, as investors scrutinize the biotech’s transition from clinical-stage development to commercial ...

Netsol Technologies CEO Najeeb Ghauri buys $19,500 in stock ...

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close. Beam Therapeutics' (BEAM +0.00%) base-editing approach enables the company to rewrite ...